Percutaneous Edge-to-Edge Mitral Valve Repair in High-Surgical-Risk Patients

Branden, Ben J L Van den; Swaans, Martin J.; Post, Martijn C.; Rensing, Benno J.; Eefting, Frank D.; Jaarsma, Wybren; Heyden, Jan A.S. Van der

doi:10.1016/j.jcin.2011.09.013

Cited by 47 publications

(48 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no difference in the rates of death and MR at four years follow-up, but a greater need for reoperation at one (MitraClip 20.4% vs. 2.2%, p<0.001) and four years (24.8% vs. 5.5%, p<0.001) [6]. Several series have reported outcomes in high-risk patients with MR after MitraClip, but only few with results beyond the peri-operative period [7][8][9][10][11][12][13][14][15]. A recently published systematic review has reported significantly lower observed than predicted surgical risk of mortality at 30 days (between 0% -7.8%); and lower grade of MR, NYHA class and improved quality of life after percutaneous mitral valve repair compared to pre-operative baseline [16].…”

Section: Resultsmentioning

confidence: 96%

“…There are few series of high-risk patients undergoing percutaneous mitral valve repair which report follow-up beyond 30 days [16]. In a recent systematic review of highrisk patients undergoing MitraClip, mortality at 30 days ranged between 0 and 7.8% [16]; survival is above 85% at six months in four reports including six-month follow-up [12][13][14][15]. The EVEREST high-risk registry comprised a cohort of high-risk patients undergoing MitraClip (STS score !12%) that was compared with a cohort of similarly high-risk patients managed conservatively [15].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Mitral Valve Repair in a High-risk Australian Series

Edelman

Dias

Passage

et al. 2014

Heart, Lung and Circulation

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Percutaneous Mitral Valve Repair in a High-risk Australian Series

Edelman

Dias

Passage

et al. 2014

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…In the early postoperative course, the MAE Multimorbidity, high-risk patient, contraindication for oMVS: log EuroScore > 20% and/or STS-Score >10% 11,13,14,19,21,24,26,31,35,42,43,48,49 AHA/ASC/ESC criteria for oMVS fulfilled [10][11][12]20,21,38,40,43,45,47,50 Previous cardiac surgery 13,14,20,26,40,45 Echocardiographic criteria for treatment with MitraClip system fulfilled 8,9,19,32,33 Chest radiation/porcelain aorta 8,9,16,26,45,51 Possible indications…”

Section: Recommendations For Structural Procedural and Documentatiomentioning

confidence: 99%

The MitraClip System: A Systematic Review of Indications, Procedural Requirements, and Guidelines

Bail

Doebler

2013

Thorac cardiovasc Surg

View full text Add to dashboard Cite

Background Transcatheter interventions (TIs) are new treatment options for patients with severe mitral valve regurgitation (MR) who cannot undergo open mitral valve surgery (oMVS). Despite the lack of scientific evidence demonstrating the benefit of these procedures, there has been a steady increase in their use. The aim of this study was to evaluate whether there are any indication criteria, process, and structural requirements, or scientific society and institutional guidelines for the use of the MitraClip System (Abbott Vascular-Structural Heart, Menlo Park, California, United States). Method A systematic literature search was conducted using the common medical and scientific databases. Of a total of 1,395 publications, 42 publications met the inclusion criteria and were included for the evaluation. Results Despite a general lack of high-quality evidence and of consensus recommendations from scientific societies or institutions, an assessment of indication criteria and process and structural requirements for the use of the MitraClip System, including noncontrolled studies, was possible. The majority of studies agree that an interdisciplinary heart team including a cardiothoracic surgeon, an interventional cardiologist, and an echocardiographic specialist should actively participate in clinical decision making, and in the procedure itself. Participation in a scientific-based registry is strongly recommended. Conclusions The MitraClip System is a promising procedure, but evidence-based indication criteria, structural, and process requirements for its use are lacking. Further results from prospective, randomized controlled trials are needed to determine patients, potential adverse events, device durability, and long-term follow-up. MitraClip should be used in only a small number of centers with procedure-specific, high-quality surgical and interventional experience, and training.

show abstract

“…The recent introduction of MitraClip ® , the first percutaneous mitral valve repair device, provides a third therapeutic option for severe MR patients [7]. A growing body of evidence supports the increased uptake of this new therapy [8][9][10][11][12][13][14][15]. Consequently, the 2012 European Society of Cardiology guidelines suggested the use of percutaneous repair in patients with an indication for valve surgery, but judged inoperable or at unacceptably high surgical risk [16,17].…”

Section: Introductionmentioning

confidence: 99%